JSH-23

JSH-23 is a small molecule inhibitor that specifically targets the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. It functions by selectively inhibiting the nuclear translocation of the NF-κB p65 subunit without affecting the degradation of IκBα. By preventing the entry of p65 into the nucleus, JSH-23 effectively blocks the transcriptional activation of various pro-inflammatory, pro-fibrotic, and pro-survival genes. In preclinical research, JSH-23 is widely utilized as a pharmacological tool to investigate the role of NF-κB in diverse pathological conditions, including hypertensive heart disease, various cancers (such as lung, breast, and liver cancers), neurodegenerative disorders like Alzheimer's disease, and chronic inflammatory conditions like prostatitis and osteomyelitis. It has demonstrated efficacy in animal models for reducing inflammation, attenuating tissue fibrosis, and restoring mitochondrial function.

Other names

4-Methyl-N1-(3-phenylpropyl)benzene-1,2-diamine4-Methyl-N1-(3-phenylpropyl)-1,2-benzenediamine